secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amylyx Pharmaceuticals, Inc. (AMLX)
CIK:        0001658551
Form:       8-K
Filed at:   2026-08-18T11:09:58+00:00
Accession:  0001193125-26-354716
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amylyx reports positive Phase 3 LUCIDITY results for avexitide in post-bariatric hypoglycemia
--------------------------------------------------------------------------------

- LUCIDITY met primary endpoint: 55% reduction in composite Level 2/3 hypoglycemic events vs placebo (p=0.000003).
- All secondary endpoints met: reductions in SMBG-measured Level 2, CGM-measured Level 2, and adjudicated Level 3 events.
- Trial enrolled 78 adults with PBH post-RYGB; randomized 3:2 to 90 mg avexitide SC daily or placebo.
- NDA submission to FDA planned by end of 2026; avexitide has Breakthrough Therapy and Orphan Drug designations.
- Avexitide well-tolerated; no serious AEs related to treatment; common AEs: diarrhea, injection site erythema, bruising.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658551/000119312526354716/0001193125-26-354716-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658551/000119312526354716/d180533d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-354716

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer